Oncolytics Biotech Inc.

Oncolytics Biotech Inc. is developing REOLYSIN®, a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that targets cancer through a unique mechanism of action with two components, selective tumor lysis and activation of the innate and adaptive immune systems, creating an inflamed phenotype to treat a variety of solid tumors and hematological malignancies.

 

Bank Name Oncolytics Biotech Inc.
Stock Exchange NASDAQ
Symbol ONCY
Sector Healthcare
Industry Major Pharmaceuticals
Country United States
World Region Amarica
Chairman
CEO Dr. Matthew C. Coffey
Employees
Website www.oncolyticsbiotech.com
Registered Year 1998

 

UpdateContent
UpdateContent
UpdateContent